CELMoDs

Mechanism

Also known as: CELMoDs

Related News

C4 Therapeutics Doses First Patient in Phase 2 Myeloma Trial, Targets 2028 NDA Submission

Mar 08, 2026

C4 Therapeutics has initiated its Phase 2 MOMENTUM trial of cemsidomide in relapsed/refractory multiple myeloma, targeting enrollment completion in Q1 2027 and a registrational dataset by 2028. The company plans a combination study with elranatamab in Q2 2026.

CELMoDs and CAR T-Cell Therapies Show Promise in Multiple Myeloma Treatment

Feb 27, 2026

Novel CELMoD agents are being evaluated to address T-cell exhaustion in multiple myeloma patients, while CAR T-cell therapy CARVYKTI shows longer-term survival benefits. Nearly 200,000 people in the U.S. live with this blood cancer.